UBE2N Emerges as Novel Prognostic Biomarker and Therapeutic Target in Lung Adenocarcinoma
Key Insights
UBE2N (search) expression is significantly elevated in lung adenocarcinoma tissues and correlates with poor patient prognosis, advanced disease staging, and reduced overall survival across multiple independent cohorts.
High UBE2N (search) expression promotes an immunosuppressive tumor microenvironment characterized by increased neutrophil infiltration and reduced CD8 (search)+ T cell activity, leading to resistance to immune checkpoint blockade therapy.
UBE2N (search) knockdown significantly impairs lung adenocarcinoma cell proliferation, migration, and invasion while increasing apoptosis, establishing its role as an oncogenic driver and potential therapeutic target.
Lung adenocarcinoma (LUAD) represents the most prevalent subtype of non-small cell lung cancer, accounting for approximately 50% of all lung malignancies and serving as a leading cause of cancer-related mortality worldwide. Despite recent advances in targeted therapies and immunotherapy, the five-year survival rate remains at approximately 15%, highlighting the urgent need for novel prognostic biomarkers and therapeutic targets.
UBE2N Identified as Key Prognostic Factor
Through comprehensive multi-cohort screening of antiviral-related genes, researchers identified UBE2N (search) (ubiquitin-conjugating enzyme E2 N) as a robust prognostic predictor in LUAD. The study analyzed multiple datasets including TCGA (search)-LUAD and several Gene Expression Omnibus cohorts, revealing that UBE2N expression was significantly upregulated in tumor tissues compared to normal lung tissue.
Survival analysis across multiple independent cohorts consistently demonstrated that patients with high UBE2N (search) expression experienced significantly shorter overall survival. In the TCGA (search)-LUAD cohort, high UBE2N expression was associated with advanced T-stage (T2-T4), higher disease stage (II-IV), and distant metastasis (M1). Multivariate Cox regression analysis confirmed UBE2N as an independent prognostic factor with a hazard ratio of 2.19 (95% CI: 1.63-2.95, p < 0.001).
Tumor Microenvironment Remodeling
UBE2N (search) expression significantly impacts the tumor immune microenvironment in LUAD. Tumors with high UBE2N expression exhibited increased infiltration of neutrophils, γδT cells, and Th2 cells, while showing reduced infiltration of effector immune cells including B cells, CD8 (search)+ T cells, dendritic cells, NK cells, and memory T cells.
The high-UBE2N (search) group demonstrated markedly higher tumor purity and lower stromal, immune, and ESTIMATE scores compared to the low-UBE2N group. This pattern suggests that UBE2N promotes an immunosuppressive microenvironment that facilitates tumor progression and immune evasion.
Immunotherapy Resistance Mechanisms
CRISPR screening data revealed that UBE2N (search) knockdown promoted T cell-mediated tumor killing and enhanced MHC-I (search) expression. Analysis of real-world immunotherapy cohorts showed that patients with low UBE2N expression exhibited significantly prolonged survival when receiving immune checkpoint blockade therapy.
The Immunophenoscore analysis demonstrated that the low-UBE2N (search) group had significantly higher scores than the high-UBE2N group, independent of CTLA-4 (search) expression patterns. In multiple immunotherapy cohorts, patients in the responsive group exhibited lower tumoral UBE2N expression, with ROC curve analysis confirming UBE2N's predictive value for immunotherapy response.
Functional Validation and Therapeutic Implications
Experimental validation using tissue microarrays confirmed significantly elevated UBE2N (search) expression in LUAD tissues versus paired normal tissues. Functional studies demonstrated that UBE2N knockdown in A549 lung adenocarcinoma cells resulted in a 75% reduction in expression and significantly impaired cell proliferation over time.
Cell migration and invasion assays revealed that UBE2N (search) knockdown markedly reduced the migratory and invasive capabilities of LUAD cells. Additionally, UBE2N silencing significantly enhanced apoptosis, with increased late apoptosis and a modest rise in early apoptosis compared to control cells.
Drug Sensitivity Patterns
Chemosensitivity analysis revealed complex patterns of drug response associated with UBE2N (search) expression. While high-UBE2N tumors showed sensitivity to conventional chemotherapeutic agents including docetaxel, 5-fluorouracil, cisplatin, and cyclophosphamide, they exhibited resistance to several targeted agents such as ribociclib, selumetinib, and ibrutinib.
Connectivity mapping identified three potential therapeutic compounds showing inverse transcriptomic alterations with UBE2N (search): genistein, GSK-1059615, and 3-deazaadenosine. Previous studies have reported the inhibitory effects of genistein and 3-deazaadenosine on lung cancer growth, supporting these findings.
Clinical Implications
The study's findings establish UBE2N (search) as both a prognostic biomarker and potential therapeutic target in LUAD. The protein's role in promoting tumor progression through metabolic reprogramming, DNA repair enhancement, and immune evasion provides multiple avenues for therapeutic intervention.
A prognostic nomogram integrating UBE2N (search) expression with clinical variables demonstrated excellent predictive performance, with calibration curves showing good agreement between predicted and observed outcomes. Decision curve analysis confirmed that the nomogram and UBE2N-based risk score provided significant clinical benefit over baseline models.
Mechanistic Insights
Functional enrichment analysis revealed that UBE2N (search)-associated genes were enriched in pathways related to cell cycle regulation, DNA replication, and proteasome function. High-UBE2N tumors showed predominant enrichment in ribosome, cell cycle, and oxidative phosphorylation pathways, while low-UBE2N tumors were associated with immune-related pathways including B cell receptor signaling and allograft rejection.
The study suggests that UBE2N (search) promotes tumor progression through enhanced metabolic activity and DNA repair capacity, enabling tumors to survive under stress conditions while simultaneously suppressing anti-tumor immune responses.
These comprehensive findings position UBE2N (search) as a promising biomarker for patient stratification and a potential target for developing novel therapeutic strategies in lung adenocarcinoma, particularly for overcoming immunotherapy resistance and improving patient outcomes.